Invitation to presentation of Isofol´s report for the fourth quarter of 2022
GOTHENBURG, Sweden, February 9, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will publish the company’s results for the fourth quarter of 2022 on Wednesday, February 22, 2023. On the same day, Isofol invites investors, analysts, and media to an audiocast with a subsequent question and answer session.
In conjunction with the publication of the interim report for the fourth quarter of 2022, Isofol invites investors, analysts, and media to an audiocast on February 22, 2023 at 11:00 a.m. CET. The presentation will be held by Isofol´s CEO Ulf Jungnelius and CFO Gustaf Albèrt, who will present and comment on the report, followed by a Q&A-session. The presentation will be held in English.
Date and time
February 22, 2023, at 11:00 a.m. CET
Link to audiocast
If you wish to participate via the web and ask written questions, please use the link below:
https://ir.financialhearings.com/isofol-medical-q4-2022
Teleconference
If you wish to participate via teleconference, please register using the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference:
https://conference.financialhearings.com/teleconference/?id=5002218
The presentation will also be available on Isofol’s website after the broadcast:
https://isofolmedical.com/company-presentations/
For further information, please contact
Isofol Medical AB (publ)
Ulf Jungnelius, M.D., Chief Executive Officer
E-mail: jungnelius@isofolmedical.com
Phone: +46 (0) 709 16 89 55
Gustaf Albèrt, CFO
E-mail: gustaf.albert@isofolmedical.com
Phone: +46 (0)709-16 83 02
The information was submitted for publication, through the agency of the contact person set out above, at 14.30 CET on February 9, 2023.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is a clinical-stage biotechnology company that has focused its operations on developing and improving the current standard treatment for patients suffering from cancer by increasing treatment efficacy through the use of cytostatics. Isofol’s ambition was to develop a drug for first-line treatment of advanced colorectal cancer (mCRC), thereby seeking to improve the current clinical practice by realizing the full strength of 5-FU with the addition of arfolitixorin. Isofol has an exclusive global licensing agreement with Merck & Cie in Schaffhausen, Switzerland, to develop and commercialize arfolitixorin in oncology. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.